focus -WSS

focus

author：explore 2025-10-02 21:06:24 - browse：7121

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

WSS

FDA advisers vote against ALS treatment from BrainStorm

Risky weight loss products often used by teens globally, per study

Heart disease and mental health: A look at cardiac psychology

Idaho abortion case may prompt more restrictions in other states

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Wikipedia

focus

focus

New air purifier tech could be key to improving indoor air quality

Intercept Pharmaceuticals sells itself for less than $1 billion

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How I ended up pumping milk in a bathroom stall at JPM 2024

23andMe had bad news about my health. I wish a person had delivered it

STAT Virtual Event: How to Increase Diversity in Clinical Trials

DIEP, the 'gold standard' of breast reconstruction, is under threat

The SUPPORT Act is critical to fighting the opioid crisis

In age of alternative facts, a scholarly course on calling out crap

Idaho abortion case may prompt more restrictions in other states

Wikipedia

New Medicare drug pricing powers could soon be upended in court

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Did you have Obamacare on your GOP debate bingo card?

Sudafed saga points to U.S. issues with evaluating older drugs

After a drawn out lobbying fight, ARPA

Would Medicare drug price negotiations stall in a shutdown?

entertainment

hotspot

focus

knowledge